<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160185</url>
  </required_header>
  <id_info>
    <org_study_id>114015</org_study_id>
    <nct_id>NCT01160185</nct_id>
  </id_info>
  <brief_title>Meta-analysis of Efficacy of Topotecan</brief_title>
  <official_title>Meta-analysis of Efficacy of Topotecan and Other Treatments for Recurrent Carcinoma of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This meta-analysis was conducted to investigate the efficacy of Topotecan and other
      treatments for recurrent and stage IVB carcinoma of the cervix
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies included in the meta-analysis were: GOG-0179, GOG-0204 &amp; GOG-0169
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Cervical Intraepithelial Neoplasia</condition>
  <arm_group>
    <arm_group_label>cisplatin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>cisplatin + topotecan</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>cisplatin + paclitaxel</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>paclitacel</description>
    <arm_group_label>cisplatin + paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin monotherapy</description>
    <arm_group_label>cisplatin</arm_group_label>
    <arm_group_label>cisplatin + paclitaxel</arm_group_label>
    <arm_group_label>cisplatin + topotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan</intervention_name>
    <description>topotecan</description>
    <arm_group_label>cisplatin + topotecan</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The search was designed to identify all clinical data published since the Cancer Care
        Ontario systematic review in 2006. The Cancer Care Ontario systematic review searched
        MEDLINE (1966 to February 2006), EMBASE (1980 to February 2006), the Cochrane Library
        (Cochrane Database of Systematic Reviews (2006 Issue 1), and Cochrane Controlled Trials
        Register (2006 Issue 1)), the Canadian Medical Association Infobase, and the National
        Guidelines Clearinghouse. The conference proceedings of the American Society of Clinical
        Oncology (1995-2005) and the European Society of Medical Oncology (2002-2005) were also
        searched. The search was conducted on 18 December 2008.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Randomised Clinical Trials or systematic reviews or meta-analyses

          -  Treatment with topotecan or platinum-based single and combination regimens in female
             patients of any race with cancer of the cervix recurrent after radiotherapy or stage
             IVB disease

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>July 8, 2010</last_update_submitted>
  <last_update_submitted_qc>July 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

